Clinical Trials

A Phase I Study of AC220 plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia

Protocol
11-160
Full Title
A Phase 1 Study of AC220 (ASP2689) in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia
Purpose

The standard therapy for acute myeloid leukemia (AML) includes the drugs cytarabine and daunorubicin. However, despite this treatment, many patients succumb to the disease.

AC220 is an investigational drug which works by blocking certain targets on cancer cells (enzymes called “receptor tyrosine kinases,” or RTKs). It appears to work best in patients with AML who have mutations in the FLT3-ITD gene. In prior studies, some patients with AML achieved remission after receiving AC220 alone.

The purpose of this study is to find the highest dose of AC220 that can be given safely with cytarabine and daunorubicin in patients with AML who have not yet received treatment.

Investigator
Martin S. Tallman, MD -- Chief, Leukemia Service
Martin S. Tallman - Physician Profile
Co-Investigators
Dan Douer, MD -- Leader, Acute Lymphoblastic Leukemia Program
Dan Douer - Physician Profile
Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of AML.
  • Patients may not have received prior therapy for their AML.
  • Patients must be aged 18-60.

For more information about this study and to inquire about eligibility, please contact Dr. Martin Tallman at 212-639-3842.

Disease(s)
Leukemia
Leukemia: Acute Myelocytic Leukemia
Leukemia: Acute Myelogenous Leukemia
Locations
ClinicalTrials.gov
Related Diseases